Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services
SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life sciences company, has selected Fluidigm’s CyTOF® technology and the industry-leading Maxpar® Direct™
View HTML
Toggle Summary Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark study demonstrates the potential for Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System
View HTML
Toggle Summary Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019
Fourth quarter preliminary revenue of $32.0-32.4 million Fiscal year preliminary revenue of $116.7-117.2 million Mass cytometry revenue increased approximately 23 percent for the full fiscal year SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM)
View HTML
Toggle Summary MOgene Selects Fluidigm Advanta Assays and Juno System to Expand Its NGS Services Portfolio
Fluidigm microfluidics technology to fuel growth in genomics services SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- MOgene, a leading provider of genomic and bioinformatic services in St. Louis , today announced it has selected Fluidigm’s (NASDAQ:FLDM) Advanta™ assays and
View HTML
Toggle Summary The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping
SOUTH SAN FRANCISCO , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab , a hub for collaborative
View HTML
Toggle Summary Fluidigm Named to Greater Toronto's Top Employers for 2020
Competition Recognizes Employers with Exceptional HR Programs and Forward-Thinking Workplace Policies SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Fluidigm Canada, a subsidiary of Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
View HTML
Toggle Summary Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging
Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced
View HTML
Toggle Summary Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System
2019 Gold Award for Best New Product in Cell Biology Awarded to Fluidigm SOUTH SAN FRANCISCO, Calif. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc. , the leading research and advisory firm serving the life science tools market, recognized  Fluidigm (NASDAQ:FLDM) with the Gold Award for the
View HTML
Toggle Summary Fluidigm Corporation Announces Pricing of Private Offering of $50 Million of 5.25% Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the pricing of $50 million aggregate principal amount of 5.25%
View HTML
Toggle Summary Fluidigm Corporation Announces Proposed Private Offering of $45 Million of Convertible Senior Notes
SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it intends to offer, subject to market conditions and other
View HTML